The estimated Net Worth of Timothy Norris Irish is at least $7.65 Thousand dollars as of 3 March 2022. Timothy Irish owns over 5,500 units of Icad Inc stock worth over $7,645 and over the last 3 years Timothy sold ICAD stock worth over $0.
Timothy has made over 1 trades of the Icad Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Timothy bought 5,500 units of ICAD stock worth $25,465 on 3 March 2022.
The largest trade Timothy's ever made was buying 5,500 units of Icad Inc stock on 3 March 2022 worth over $25,465. On average, Timothy trades about 1,833 units every 0 days since 2022. As of 3 March 2022 Timothy still owns at least 5,500 units of Icad Inc stock.
You can see the complete history of Timothy Irish stock trades at the bottom of the page.
Timothy's mailing address filed with the SEC is 98 SPIT BROOK ROAD, SUITE 100, , NASHUA, NH, 03062.
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton, and Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: